(TheNewswire)
Toronto, Ontario /TheNewswire/ November 29, 2018
– Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT,
OTCQB:VPTDF) is pleased to announce that it will be exhibiting at EuroEcho 2018, the annual congress
of the European Association of Cardiovascular Imaging to showcase the next-generation VMS+ System.
With nearly 4,000 healthcare professionals from over 90 countries around the world, EuroEcho is one
of the world’s largest cardiovascular imaging congresses and is a premier place to meet with world-renowned global experts in the
field of cardiovascular imaging. Ventripoint will be exhibiting in booth D400 at EuroEcho held in Milan, Italy from December
5th – 7th providing hands-on
demonstrations of the next-generation VMS+ System.
On December 8th at 8:30 AM, Dr. Shelby Kutty of
Nebraska Children’s Hospital will be presenting a poster in section P1694 on a comparative study performed with the VMS+ System
“Application of knowledge-based reconstruction to three-dimensional
echocardiography and comparison with semiautomatic border detection method for evaluating ventricular function”.
The next-generation VMS+ System is designed to use Artificial Intelligence (AI) to provide a
streamlined approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo
images. Artificial Intelligence (AI) is the future of cardiac imaging and is transforming clinical outcomes. After clinician
feedback, we re-designed the system to incorporate an improved user interface and smaller footprint, thereby allowing for superior
integration into the clinical echography workflow and environment. The 3D guidance tracking system has also been replaced with an
innovative tracking sensor technology to enable patient repositioning during the examination.
“We are excited to showcase our next-generation VMS+ System to the European market. We will have
live scanning in the booth to provide the opportunity for hands-on use by the cardiology community,” notes Mehran Mehrtash,
Vice-President, Worldwide Distributor Sales of Ventripoint Diagnostics.
This product is not commercially available for sale and is for investigational use only.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information, please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.